United States · Platforms & data · MarketBeat
Milestone Pharmaceuticals Q3 Earnings Call Highlights
Detailed summary
Milestone Pharmaceuticals (NASDAQ:MIST) plans to cut operating expenses by approximately 30% as it seeks to extend its cash runway while building sales of CARDAMYST and advancing a late-stage clinical trial. The company reported approximately 1,800 CARDAMYST prescriptions in the third quarter of 20
MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.marketbeat.com)
